Switch to
More onapp

How to use scorecard? Learn more

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹28,590 cr, stock is ranked 179
Moderate RiskStock is 2.09x as volatile as Nifty
242.352.90 (+1.21%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't faired well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
MidcapWith a market cap of ₹28,590 cr, stock is ranked 179
Moderate RiskStock is 2.09x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
61.79
PB RatioPB Ratio
3.02
Dividend YieldDiv. Yield
0.63%
Sector PESector PE
32.83
Sector PBSector PB
4.48
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

67%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Brands

Biocon

Biotech company

Investor PresentationView older 

May 24, 2023

PDF
View Older Presentations

Brands

Biocon

Biotech company

Financial TrendFinancial statements 

20202021202220236.537.418.4011.550.750.740.650.46
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 3.25%

See detailed holdings

Recent EventsAll events 

Related Party Transactions 
Announced OnMay 26, 2023

Biocon Limited has informed the Exchange about related Party Transactions | Download

Biocon Limited has informed the Exchange about related Party Transactions | Download

Annual Secretarial Compliance Report 
Announced OnMay 25, 2023

Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download

Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru. | Download

Cash Dividend 
Ex. DateJun 30, 2022

Final • Div/Share: ₹ 0.5

See all events